Jon P. Stonehouse - Jan 11, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
President & CEO, Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Jan 11, 2022
Transactions value $
-$1,897,040
Form type
4
Date filed
1/13/2022, 03:45 PM
Previous filing
Sep 1, 2022
Next filing
Jun 16, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $870K +184K +20.41% $4.73 1.09M Jan 11, 2022 Direct F1
transaction BCRX Common Stock Sale -$2.77M -184K -16.95% $15.04 902K Jan 11, 2022 Direct F1, F2
holding BCRX Common Stock 5K Jan 11, 2022 By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
holding BCRX Common Stock 5K Jan 11, 2022 By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -184K -100% $0.00* 0 Jan 11, 2022 Common Stock 184K $4.73 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on March 1, 2012 and would have expired on March 1, 2022.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $15.00 to $15.10. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.